Market Place
Sourcing Support
Recludix Names STAT6 Inhibitor Candidate Under Sanofi Deal
02 Jun 2025 //
GLOBENEWSWIRE
Recludix Pharma Shows STAT6 Inhibitor Efficacy in Asthma Model
19 May 2025 //
GLOBENEWSWIRE
Recludix Presents Data on First-in-Class BTK SH2 Domain Inhibitor
07 May 2025 //
GLOBENEWSWIRE
Recludix Pharma to Present at Oppenheimer Healthcare Conference
10 Feb 2025 //
GLOBENEWSWIRE
Recludix to Present at Annual J.P. Morgan Healthcare Conference
10 Jan 2025 //
GLOBENEWSWIRE
Recludix Pharma to Attend Two Investor Conferences in December
25 Nov 2024 //
GLOBENEWSWIRE
Recludix Pharma Presents Oral STAT3 Inhibitor Data in Arthritis
14 Nov 2024 //
GLOBENEWSWIRE
Fierce Biotech Names Recludix Pharma a “Fierce 15” Biotech Company of 2024
05 Aug 2024 //
GLOBENEWSWIRE
Recludix Data Shows Oral STAT3 Inhibitor Efficacy, Safety
17 May 2024 //
GLOBENEWSWIRE
Recludix Pharma Appoints Dr. Ajay Nirula as EVP, Head of R&D
23 Apr 2024 //
GLOBENEWSWIRE
Recludix Pharma to Participate in Two Investor Conferences in March
28 Feb 2024 //
GLOBENEWSWIRE
Recludix Pharma to Present at Two Investor Conferences in February
06 Feb 2024 //
GLOBENEWSWIRE
Recludix Pharma to Present at Two Investor Conferences in November
09 Nov 2023 //
GLOBENEWSWIRE
Recludix Pharma Presents Data Demonstrating Efficacy Profile of REX-7117
31 Oct 2023 //
GLOBENEWSWIRE
Recludix Pharma Presents Preclinical Data from its STAT3 Inhibitor Program
17 Oct 2023 //
GLOBENEWSWIRE
Recludix Pharma to Participate in Multiple Investor Conferences in September
30 Aug 2023 //
GLOBENEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.